Articles tagged with Antiretrovirals
A study published in The Lancet suggests that clinical monitoring is as effective as using CD4 count or viral load measures in advising when to switch to second-line ART. This finding has implications for resource-limited settings where access to laboratory tests may be limited.
A study published in The Lancet found that recent use of abacavir and didanosine was associated with an increased rate of heart attacks, while cumulative use showed no association. The researchers suggest underlying biological mechanisms may be responsible for the increased risk.
A study suggests that accelerating efforts to provide antiretroviral therapy (ART) in South Africa could prevent over 1.2 million AIDS-related deaths by 2012, with full access reducing projected deaths to 800,000. Current treatment capacity would lead to 2.4 million deaths.
The article discusses the controversy surrounding when to initiate antiretroviral treatment in children with HIV. Dr. Steven Welch argues for deferred treatment to avoid poor adherence habits and drug resistance, while Professor Di Gibb advocates for early initiation to prevent disease progression and promote healthy growth.
Researchers found that HIV persists in the gut despite long-term antiretroviral therapy, which failed to eradicate the virus from gut-associated lymphoid tissue. B-cell abnormalities also persisted, with memory B cells failing to recover after treatment.
A study by the University of Copenhagen found that HIV medications Abacavir and Didanosine significantly increase the risk of heart attacks in patients. The risk is higher for those with pre-existing cardiovascular conditions, but can be mitigated by stopping use of these drugs.
A new study suggests that antiretroviral drugs used to treat HIV can also protect people from getting the AIDS virus, especially when two drugs are taken in combination before exposure to the virus. The best protection was seen in macaques that received a combination of two drugs, with all being protected from infection.
Researchers at UT Southwestern Medical Center have discovered that anti-retroviral drugs given daily before and after exposure to HIV can prevent vaginal transmission of the virus. This breakthrough could empower women worldwide to protect themselves from HIV infection.
A large study found that depression significantly worsens HIV treatment adherence and clinical measures, but antidepressant medication can improve outcomes. Depressed patients had lower adherence rates and worse viral therapy responses compared to non-depressed patients.
A study of 7916 patients found that the cumulative risk of triple-class failure was estimated at 9.2% by 10 years, with evidence suggesting a decrease in this rate over time. Despite extensive failure, many patients retained some virological activity post-failure, and the risk of death was lower than expected.
A recent clinical trial has shown that tesamorelin can decrease deep abdominal fat by 15% and improve blood lipid levels in patients with HIV/HAART-associated Lipodystrophy Syndrome. The treatment has minimal side effects, offering a therapeutic breakthrough for many patients.
A combination of common anti-HIV drugs tenofovir and emtricitabine with nevirapine during labor significantly reduces the risk of HIV-positive pregnant women developing resistance to a class of drugs, potentially improving future treatment options.
A new study published in JAMA found that antiretroviral drug therapy and non-physician care, such as nursing, are essential in saving the lives of HIV-infected African children. The research showed significant improvements in CD4 cell counts and weight-for-age scores among children treated with antiretrovirals.
Researchers found that patients who openly discussed their HIV status had better adherence to medication regimens and lower rates of treatment failure. Free medication and social support also increased the chances of patients continuing treatment.
A clinical trial by NIAID suggests that early antiretroviral therapy for HIV-infected infants can significantly improve survival rates. The study found that children treated before three months of age had a better prognosis than those whose treatment was delayed, leading to a potential change in standard care worldwide.
Researchers have developed an induction-maintenance treatment strategy that balances viral suppression with minimal harm to patients. The model suggests six to ten months of induction therapy can achieve durable suppression of HIV, making it a promising approach for eradicating resistant viruses.
Several phase II and III trials investigate anti-retroviral drug combinations for pre-exposure prophylaxis among at-risk populations. The implementation of such a program requires careful planning and substantial resources to ensure access, minimize risk behavior, and prevent drug-resistant strains.
A new NNRTI etravirine has been shown to be effective in suppressing HIV viral load in treatment-experienced patients with documented resistance to non-nucleoside reverse transcriptase inhibitors. The DUET trials 1 and 2 found that 56% and 62% of patients achieved viral loads below 50 copies/mL, respectively.
Researchers analyze success of HIV entry inhibitors, highlighting need for new classes due to increasing resistance and toxicity concerns. The study concludes that blocking HIV entry by fusion inhibitors and coreceptor antagonists holds major promise for developing a new antiretroviral drug class.
The HIV Medicine Association strongly opposes The Gambia's use of an unproven herbal remedy for treating HIV/AIDS. The organization urges patients to resume taking their prescribed antiretroviral medications, which have been shown to save lives in Africa.
A study by Ugandan researchers found that interruptions in antiretroviral medication supply due to financial or logistical issues led to the development of drug resistance in HIV-infected patients. Despite near-perfect adherence, treatment interruptions created opportunities for resistance to develop.
A new class of anti-HIV drugs has proven effective in a clinical trial by inhibiting the integrase enzyme, leading to a significant drop in HIV RNA levels and an increase in CD4 cells. The study suggests that this drug could become an important component of combination treatment regimens for heavily pretreated patients.
A new antiretroviral drug darunavir has been shown to be highly effective in treating HIV when used in conjunction with a boosting dose of the existing drug ritonavir. The study found that 61% of patients taking the new drug achieved a ten-fold drop in HIV RNA levels, compared to just 15% of those on the control group.
African scientists will receive training in drug discovery techniques to combat diseases such as HIV, tuberculosis, and malaria. The program aims to develop affordable, effective drugs using low operating costs and socially conscious investments.
A recent study published in PLOS ONE found that antiretroviral resistance testing significantly improves life expectancy and quality of life for HIV patients. The study also revealed cost savings for society, including reduced healthcare costs and increased productivity.
Thai researchers discovered that patients failing first-line antiretroviral therapy are also resistant to similar drugs, leaving few options for replacement therapies. The lack of affordable virus-detection tests hinders early detection and treatment adjustments.
Researchers found that continuous antiretroviral therapy significantly reduces the risk of opportunistic diseases and death compared to episodic therapy. The study also showed no reduction in serious side effects with continual ART.
Researchers have discovered HIV replication in resident immune cells of the testis, providing an explanation for the persistence of virus in semen. The study suggests that the testis may be a pharmacological sanctuary for the virus.
A novel home-based approach to AIDS care has been shown to improve adherence and response to antiretroviral therapy in rural Uganda. The study, published in The Lancet, found that good adherence was associated with sustained suppression of HIV during the first year of treatment.
A new study finds that a community-driven approach to distributing anti-AIDS medications is more equitable and effective than traditional top-down methods. Patients treated through this model showed significant increases in CD4 counts, indicating improved immune system function.
A study of 765 patients with HIV-1 infection found no significant differences between the two regimens in reducing HIV levels, time to virologic failure, or adverse events. The researchers concluded that adding a fourth drug did not provide additional benefits but may increase complexity and costs.
The International AIDS Society-USA Panel has updated guidelines for the treatment of adult HIV infection, recommending antiretroviral therapy for all symptomatic and asymptomatic adults with CD4 counts below 350/μL. The new guidelines also emphasize the importance of adherence to therapy and regular monitoring of plasma HIV-1 RNA levels.
Research reveals that African HIV-infected patients have significantly higher rates of adherence to antiretroviral regimens, with 77% taking their medications as directed compared to 59% in North America. This contradicts historical assumptions about poor adherence among Africans.
A systematic review and meta-analysis found higher ART adherence rates in sub-Saharan Africa compared to North America. The study suggests that factors beyond poverty, such as poor patient-clinician relationships and untreated depression, contribute to low adherence rates in North America.
Research by Zelalem Temesgen and colleagues found that nearly half of long-term HIV-positive patients develop resistant strains of the virus, hindering effective treatment. The authors suggest strategies such as adherence improvement and using new antiretroviral classes to improve patient outcomes.
A study suggests that increasing access to antiretroviral therapy (ART) in resource-poor countries may not reduce HIV infection rates, but rather increase transmission due to prolonged survival and increased sexual activity. Counseling patients and promoting safe sex practices are crucial in preventing the spread of the virus.
A new model by Imperial College London researchers suggests that anti-HIV drugs alone are unlikely to stop the spread of HIV and may even increase infection rates due to improved health and behavior, highlighting the importance of prevention initiatives.
Researchers found that low-income settings had higher mortality rates due to accompanying illnesses like tuberculosis, but free treatment provision was strongly associated with lower mortality. HAART should be started earlier and eligibility determined before comorbidities develop.
A new study found that early antiretroviral therapy can significantly improve CD4 cell count outcomes in HIV-infected infants. Children who started treatment between 5 months and 5 years of age were 60% less likely to experience a decline in their CD4 cell count z-score compared to those who started treatment before 5 months.
A study of 626 patients found that Black patients on HAART had a lower risk of atheroma than White and Hispanic patients. Genetic variants were associated with dyslipidemia in Hispanic patients, but not in others.
Researchers discovered racial variations in lipid levels among HIV-1 patients on protease inhibitors, which may inform the development of tailored treatment plans. These findings could also lead to earlier initiation of lipid-modifying therapies for high-risk patients.
Researchers found that a once-daily antiretroviral combination of tenofovir DF, emtricitabine, and efavirenz leads to higher viral suppression rates and fewer side effects compared to traditional regimens. The study, involving 517 patients, demonstrates the superiority of this regimen over zidovudine-lamivudine therapy.
A study of over 3,900 children with HIV found that total lymphocyte count can predict disease progression as well as CD4 cell percentage. The current WHO guidelines for starting ART are inconsistent and may lead to inadequate treatment in low-income countries.
A recent study found that 76% of treatment-experienced patients would consider using a self-injectable HIV therapy if recommended by their physician. Despite this, only one quarter of eligible patients have discussed the option with their doctors, highlighting a significant barrier to adoption.
The introduction of generic ART led to a significant decline in HIV-related deaths in India between 1997 and 2003. Accessible drugs have also reduced the incidence of opportunistic infections such as tuberculosis among immunocompromised patients.
A multi-center study of 425 HIV-positive men found that central fat loss was statistically associated with peripheral fat loss in HIV-positive men on retroviral therapy. Central fat gain was also less among HIV-positive men, with age being the strongest factor associated with increased visceral fat.
A UN report estimates over 79,500 people with HIV/AIDS were evicted, disrupting antiretroviral treatment and home-based care. WHO-AFRO should take the lead in providing humanitarian assistance to address the escalating health crisis and potential public health disaster.
A study found that antiretroviral therapy can suppress HIV RNA in breast milk, reducing mother-to-child transmission. However, the impact of therapy on HIV DNA levels is unclear, with some studies suggesting a possible delay in treatment's effectiveness.
Poorer people have been left out of past aid programs due to insufficient planning, and donors and developing countries should learn from these mistakes. Local health officials must decide who will receive therapy and live, and who will go without, despite growing demand and limited supply.
A new review of 10 studies on HIV treatment programs in developing countries found that nearly 57% of patients had undetectable HIV levels one year after starting ART. Free or low-cost ART programs have been shown to improve adherence and treatment outcomes, suggesting a significant link between access and success.
The World Bank and IMF's public health expenditure ceilings limit external financing for HIV/AIDS projects, forcing countries to allocate funds from existing budgets. This restricts the flow of desperately needed funds to combat the epidemic in developing nations.
The 3 by 5 program faces challenges in achieving its goal of treating 3 million people with HIV/AIDS, mainly due to insufficient financial resources (US$163 million vs US$174 million) and inadequate WHO staff deployment. Three countries, India, South Africa, and Nigeria, are crucial in addressing the issue, especially in Africa where o...
The study examines lessons learned from Africa's first public ARV treatment clinic in Botswana, highlighting the need for consistent care and ongoing training for staff. The clinic has successfully treated thousands of patients, but challenges persist in staffing and infrastructure.
Researchers from Johns Hopkins Medicine found a second reservoir of HIV that harbors unique viral variants, suggesting lifelong treatment is necessary to prevent re-emergence. The archival virus has not mutated to become drug-resistant, according to recent findings.
Researchers propose an equitable antiretroviral allocation strategy to ensure fair access to the life-saving drugs. The strategy considers the population's geographic distribution, healthcare facilities, and treatment goals, aiming to maximize epidemic reduction while minimizing disparities.
Researchers at Johns Hopkins Medicine found that HIV 'blips' in viral load are mathematical artifacts caused by test variations, not signs of drug resistance. The study reassures patients on HAART therapy that their medications haven't failed and provide a better understanding of when to worry about blips.
Researchers have discovered new alkaloids with antiparasitic properties, which showed efficacy in treating visceral leishmaniasis. These quinoline compounds also exhibited activity against HIV-1 and HTLV-1 retroviruses, offering potential for new treatments.
Researchers found that HIV-specific CD4+ T cell population remains intact after treatment cessation, with increased turnover and activation upon viral rebound. This suggests a potential mechanism for the immune system to respond to viral infections.
Researchers have identified IL-7 as a potent and strain-specific inducer of latent HIV-1 cellular reservoirs in individuals on virally suppressive HAART. The growth factor stimulates HIV-1 activation from resting T cells, suggesting new approaches for HIV treatment.
Researchers at Thomas Jefferson University have discovered that interleukin-7 (IL-7) can stimulate latent HIV viruses, making them vulnerable to drugs and the immune system. The new technique may lead to improved treatments for HIV infection and could be a step towards complete viral eradication.